New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 2, 2014
05:23 EDTBSXBoston Scientific reports favorable results in MADIT-CRT study
Boston Scientific reported favorable results in studies related to cardiac resynchronization therapy, or CRT, platinum chromium stent platforms and transcatheter aortic valve replacement, or TAVR. Boston Scientific announced significant findings from the continued analysis of the landmark MADIT-CRT study, demonstrating a significant and sustained survival benefit in the indicated population. The long-term results demonstrated a 41% relative reduction in the risk of death in patients who received a Boston Scientific defibrillator with CRT compared to patients who received a defibrillator alone. In addition to the mortality benefit, the results demonstrate that these patients experienced a 62% relative reduction in the risk of experiencing a first heart failure event when compared to patients who didn't receive CRT therapy. Boston Scientific released new data that continue to reinforce the advantages of platinum chromium stents. The trial compared the safety and effectiveness of the Boston Scientific Platinum Chromium Everolimus-Eluting Stent System, or PtCr EES, to the Abbott Laboratories Cobalt Chromium Everolimus-Eluting Stent System, or CoCr EES. The results show low event rates out to four years with PtCr EES confirming excellent long-term performance. At four years, the PtCr EES also continued to demonstrate advantages over the CoCr EES. The Boston Scientific Lotus Valve System advanced TAVR technology continued to demonstrate impressive performance at three months.
News For BSX From The Last 14 Days
Check below for free stories on BSX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
17:34 EDTBSXVascular Solutions announces settlement of patent lawsuit with Boston Scientific
Vascular Solutions (VASC) announced that it has reached a settlement of its patent lawsuit with Boston Scientific Corporation (BSX) relating to patents in the area of coronary guide extension catheters. Vascular Solutions filed the original lawsuit in U.S. District Court for the District of Minnesota in May 2013, alleging that Boston Scientific infringed three patents owned by Vascular Solutions related to rapid exchange guide extension technology by manufacturing and selling its Guidezilla guide extension catheter. Boston Scientific filed a counterclaim in July 2013, alleging that Vascular Solutions infringed a patent owned by Boston Scientific related to rapid exchange guide extension technology by manufacturing and selling its GuideLiner guide extension catheter. As part of the settlement agreement, all litigation between the two parties related to guide extension will be dismissed. The terms of the settlement are confidential.
July 29, 2014
10:00 EDTBSXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:43 EDTBSXBoston Scientific initiated with a Neutral at Sterne Agee
Target $13.50.
July 28, 2014
11:07 EDTBSXLeerink medical devices analyst holds an analyst/industry conference call
Medical Devices Analyst Antalffy, along with MEDACorp Specialist Arie Pieter Kappetein, MD, PhD and Bernhard Meier, MD, assess EU cardiology trends on an Analyst/Industry conference call to be held on July 31 at 3 pm.
06:32 EDTBSXJ&J dispute with Boston Scientific looks set to go to trial, NY Times says
Subscribe for More Information
July 24, 2014
10:56 EDTBSXStocks with call strike movement; NRG BSX
NRG Energy (NRG) January 35 call option implied volatility decreased 2% to 24, NRG Energy Boston Scientific (BSX) January 15 call option implied volatility decreased 2% to 25 according to IVolatility.
08:28 EDTBSXBoston Scientific sees FY operating margin approaching 20%
Subscribe for More Information
07:04 EDTBSXBoston Scientific raises FY14 adjusted EPS to 79c-83c from 77c-82c
Subscribe for More Information
07:02 EDTBSXBoston Scientific sees Q3 adjusted EPS 18c-20c, consensus 19c
Subscribe for More Information
07:02 EDTBSXBoston Scientific reports Q2 Rhythm Management revenue growth of 7%
Subscribe for More Information
07:01 EDTBSXBoston Scientific reports Q2 adjusted EPS 21c, consensus 19c
Reports Q2 revenue $1.87B, consensus $1.87B
July 23, 2014
17:10 EDTBSXBoston Scientific receives CE Mark for Agent Drug Coated Balloon
Subscribe for More Information
15:30 EDTBSXNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings consensus, include Ford (F), consensus 36c; General Motors (GM), consensus 58c; Potash (POT), consensus 46c; Caterpillar (CAT), consensus $1.52; 3M (MMM), consensus $1.91; Union Pacific (UNP), consensus $1.43; Bristol-Myers Squibb (BMY), consensus 44c; Eli Lilly (LLY), consensus 65c; Celgene (CELG), consensus 89c; Precision Castparts (PCP), consensus $3.35; Raytheon (RTN), consensus $1.59; Noble Energy (NBL), consensus 79c; Hershey (HSY), consensus 76c; Southwest Airlines (LUV), consensus 61c; Boston Scientific (BSX), consensus 19c; JetBlue (JBLU), consensus 19c.
July 22, 2014
08:25 EDTBSXBoston Scientific risk/reward favorable into Q2 results, says RBC Capital
Subscribe for More Information
July 21, 2014
16:38 EDTBSXBoston Scientific receives FDA approval for REBEL Platinum Stent system
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use